Selective serotonin reuptake inhibitor use is associated with right ventricular structure and function: The MESA-Right ventricle study

PLoS ONE

Volumn 7, Issue 2, 2012, Pages

  Ventetuolo, Corey E ^a   Barr, R Graham ^b   Bluemke, David A ^c   Jain, Aditya ^d   Delaney, Joseph A C ^e   Hundley, W Gregory ^f   Lima, Joao A C ^d   Kawut, Steven M ^g  

^a BROWN UNIVERSITY   (United States)

^b New York Presbyterian Columbia University Medical Center   (United States)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

^d JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF FLORIDA HEALTH   (United States)

^f WAKE FOREST SCHOOL OF MEDICINE   (United States)

^g UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

SEROTONIN UPTAKE INHIBITOR;

ADULT; ARTICLE; CARDIOVASCULAR MAGNETIC RESONANCE; CARDIOVASCULAR RISK; CONTROLLED STUDY; DISEASE FREE INTERVAL; DRUG EFFECT; DRUG USE; FEMALE; HEART RIGHT VENTRICLE EJECTION FRACTION; HEART RIGHT VENTRICLE ENDDIASTOLIC VOLUME; HEART RIGHT VENTRICLE ENDSYSTOLIC VOLUME; HEART RIGHT VENTRICLE FAILURE; HEART RIGHT VENTRICLE FUNCTION; HEART STROKE VOLUME; HUMAN; MALE; STRUCTURE ACTIVITY RELATION; AGED; ATHEROSCLEROSIS; CLINICAL TRIAL; DIASTOLE; ETHNOLOGY; HEART VENTRICLE; HEART VENTRICLE FUNCTION; HEART VOLUME; HISTOLOGY; MIDDLE AGED; MULTICENTER STUDY; ORGAN SIZE; PATHOPHYSIOLOGY; SEXUAL DEVELOPMENT;

AGED; AGED, 80 AND OVER; ATHEROSCLEROSIS; CARDIAC VOLUME; DIASTOLE; FEMALE; HEART VENTRICLES; HUMANS; MALE; MIDDLE AGED; ORGAN SIZE; SEROTONIN UPTAKE INHIBITORS; SEX CHARACTERISTICS; STROKE VOLUME; VENTRICULAR FUNCTION;

EID: 84857166163     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0030480     Document Type: Article

References (59)

1. Eddahibi S, Humbert M, Fadel E, Raffestin B, Darmon Ml, et al. (2001) Serotonin transporter overexpression is responsible for pulmonary artery smooth muscle hyperplasia in primary pulmonary hypertension. J Clin Invest 108: 1141-1150.
2. Abenhaim L, Moride Y, Brenot F, Rich S, Benichou J, et al. (1996) Appetite-suppressant drugs and the risk of primary pulmonary hypertension. N Engl J Med 335: 609-616.
3. Hervé P, Launay JM, Scrobohaci ML, Brenot F, Simonneau G, et al. (1995) Increased plasma serotonin in primary pulmonary hypertension. Am J Med 99: 249-254.
4. Kereveur A, Callebert J, Humbert M, Herve P, Simonneau G, et al. (2000) High plasma serotonin levels in primary pulmonary hypertension: effect of long-term epoprostenol (prostacyclin) therapy. Arterioscler Thromb Vasc Biol 20: 2233-2239.
5. Lederer DJ, Horn EM, Rosenzweig EB, Karmally W, Jahnes M, et al. (2008) Plasma serotonin levels are normal in pulmonary arterial hypertension. Pulm Pharmacol Ther 21: 112-114.
6. Guignabert C, Izikki M, Tu LI, Li Z, Zadigue P, et al. (2006) Transgenic mice overexpressing the 5-hydroxytryptamine transporter gene in smooth muscle develop pulmonary hypertension. Circ Res 98: 1323-1330.
7. Machado RD, Koehler R, Glissmeyer E, Veal C, Suntharalingam J, et al. (2006) Genetic association of the serotonin transporter in pulmonary arterial hypertension. Am J Respir Crit Care Med 173: 793-797.
8. Liu Y, Wei L, Laskin DL, Fanburg BL, (2011) Role of protein transamidation in serotonin-induced proliferation and migration of pulmonary artery smooth muscle cells. Am J Respir Cell Mol Biol 44: 548-555.
9. Marcos E, Adnot S, Pham MH, Nosjean A, Raffestin B, et al. (2003) Serotonin transporter inhibitors protect against hypoxic pulmonary hypertension. Am J Respir Crit Care Med 168: 487-493.
10. Guignabert C, Raffestin B, Benferhat R, Raoul W, Zadigue P, et al. (2005) Serotonin transporter inhibition prevents and reverses monocrotaline-induced pulmonary hypertension in rats. Circulation 111: 2812-2819.
11. Morecroft I, Pang L, Baranowska M, Nilsen M, Loughlin L, et al. (2010) In vivo effects of a combined 5-HT1B receptor/SERT antagonist in experimental pulmonary hypertension. Cardiovasc Res 85: 593-603.
12. Eddahibi S, Guignabert C, Barlier-Mur AM, Dewachter L, Fadel E, et al. (2006) Cross talk between endothelial and smooth muscle cells in pulmonary hypertension: critical role for serotonin-induced smooth muscle hyperplasia. Circulation 113: 1857-1864.
13. Kawut SM, Horn EM, Berekashvili KK, Lederer DJ, Widlitz AC, et al. (2006) Selective serotonin reuptake inhibitor use and outcomes in pulmonary arterial hypertension. Pulm Pharmacol Ther 19: 370-374.
14. Shah SJ, Gomberg-Maitland M, Thenappan T, Rich S, (2009) Selective serotonin reuptake inhibitors and the incidence and outcome of pulmonary hypertension. Chest 136: 694-700.
15. Bild DE, Bluemke DA, Burke GL, Detrano R, Diez Roux AV, et al. (2002) Multi-Ethnic Study of Atherosclerosis: objectives and design. Am J Epidemiol 156: 871-881.
16. Natori S, Lai S, Finn JP, Gomes AS, Hundley WG, et al. (2006) Cardiovascular function in Multi-Ethnic Study of Atherosclerosis: normal values by age, sex, and ethnicity. Am J Roentgenol 186: S357-365.
17. Chahal H, Johnson C, Tandri H, Jain A, Hundley WG, et al. (2010) Relation of cardiovascular risk factors to right ventricular structure and function as determined by magnetic resonance imaging (results from the Multi-Ethnic Study of Atherosclerosis). Am J Cardiol 106: 110-116.
18. Vogel-Claussen J, Finn JP, Gomes AS, Hundley GW, Jerosch-Herold M, et al. (2006) Left ventricular papillary muscle mass: relationship to left ventricular mass and volumes by magnetic resonance imaging. J Comput Assist Tomogr 30: 426-432.
19. Psaty B, Lee M, Savage PJ, Rutan GH, German PS, et al. (1992) Assessing the use of medication in the elderly: methods and initial experience in the Cardiovascular Health Study: The Cardiovascular Health Study Collaborative Research Group. J Clin Epidemiol 45: 683-692.
20. Radloff LS, (1977) The CES-D Scale: a self-report depression scale for research in the general population. Appl Psychol Meas 1: 385-401.
21. Aaron C, Tandri H, Barr R, Johnson C, Bagiella E, et al. (2009) Physical activity and right ventricular structure and function: the MESA-Right Ventricle Study. Am J Respir Crit Care Med 179.
22. Scharhag J, Schneider G, Urhausen A, Rochette V, Kramann B, et al. (2002) Athlete's heart: right and left ventricular mass and function in male endurance athletes and untrained individuals determined by magnetic resonance imaging. J Am Coll Cardiol 40: 1856-1863.
23. Dorn GW, (2007) The fuzzy logic of physiological cardiac hypertrophy. Hypertension 49: 962-970.
24. Anversa P, Levicky V, Beghi C, McDonald S, Kikkawa Y, (1983) Morphometry of exercise-induced right ventricular hypertrophy in the rat. Circ Res 52: 57-64.
25. Shiojima I, Sato K, Izumiya Y, Schiekofer S, Ito M, et al. (2005) Disruption of coordinated cardiac hypertrophy and angiogenesis contributes to the transition to heart failure. J Clin Invest 115: 2108-2118.
26. Handoko ML, de Man FS, Happé CM, Schalij I, Musters RJP, et al. (2009) Opposite effects of training in rats with stable and progressive pulmonary hypertension. Circulation 120: 42-49.
27. Wilkins MR, Ali O, Bradlow W, Wharton J, Taegtmeyer A, et al. (2010) Simvastatin as a treatment for pulmonary hypertension trial. Am J Respir Crit Care Med 181: 1106-1113.
28. Roeleveld RJ, Vonk-Noordegraaf A, Marcus JT, Bronzwaer JGF, Marques KMJ, et al. (2004) Effects of epoprostenol on right ventricular hypertrophy and dilatation in pulmonary hypertension. Chest 125: 572-579.
29. Gan CT-J, Holverda S, Marcus JT, Paulus WJ, Marques KM, et al. (2007) Right ventricular diastolic dysfunction and the acute effects of sildenafil in pulmonary hypertension patients. Chest 132: 11-17.
30. Wilhelm M, Roten L, Tanner H, Wilhelm I, Schmid J-P, et al. (2011) Gender differences of atrial and ventricular remodeling and autonomic tone in nonelite athletes. Am J Cardiol 108: 1489-1495.
31. Coimbra R, Sanchez LS, Potenza JM, Rossoni LV, Amaral SL, et al. (2008) Is gender crucial for cardiovascular adjustments induced by exercise training in female spontaneously hypertensive rats? Hypertension 52: 514-521.
32. Ventetuolo CE, Ouyang P, Bluemke DA, Tandri H, Barr RG, et al. (2011) Sex hormones are associated with right ventricular structure and function: the MESA-Right Ventricle Study. Am J Respir Crit Care Med 183: 659-667.
33. Fetkovska N, Amstein R, Ferracin F, Regenass M, Buhler FR, et al. (1988) 5HT-kinetics and sensitivity of human blood platelets: variations with age, gender and platelet number. Thromb Haemost 60: 486-490.
34. Marazziti D, Baroni S, Masala I, Golia F, Consoli G, et al. (2010) Impulsivity, gender, and the platelet serotonin transporter in healthy subjects. Neuropsychiatr Dis Treat 6: 9-15.
35. Franke L, Schmidtmann M, Riedl A, van der Voort I, Uebelhack R, et al. (2009) Serotonin transporter activity and serotonin concentration in platelets of patients with irritable bowel syndrome: effect of gender. J Gastroenterol 45: 389-398.
36. Kawut SM, Al-Naamani N, Agerstrand C, Berman Rosenzweig E, Rowan C, et al. (2009) Determinants of right ventricular ejection fraction in pulmonary arterial hypertension. Chest 135: 752-759.
37. Kawut SM, Lima JAC, Barr RG, Chahal H, Jain A, et al. (2011) Sex and race differences in right ventricular structure and function: the Multi-Ethnic Study of Atherosclerosis-Right Ventricle Study. Circulation 123: 2542-2551.
38. Jaffre F, Bonnin P, Callebert J, Debbabi H, Setola V, et al. (2009) Serotonin and angiotensin receptors in cardiac fibroblasts coregulate adrenergic-dependent cardiac hypertrophy. Circ Res 104: 113-123.
39. Shyu K-G, (2009) Serotonin 5-HT2B receptor in cardiac fibroblast contributes to cardiac hypertrophy: a new therapeutic target for heart failure? Circ Res 104: 1-3.
40. Nebigil CG, Maroteaux L, (2003) Functional consequence of serotonin/5-HT2B receptor signaling in heart: role of mitochondria in transition between hypertrophy and heart failure? Circulation 108: 902-908.
41. O'Connor CM, Jiang W, Kuchibhatla M, Mehta RH, Clary GL, et al. (2008) Antidepressant use, depression, and survival in patients with heart failure. Arch Intern Med 168: 2232-2237.
42. Sauer WH, Berlin JA, Kimmel SE, (2001) Selective serotonin reuptake inhibitors and myocardial infarction. Circulation 104: 1894-1898.
43. Sauer WH, Berlin JA, Kimmel SE, (2003) Effect of antidepressants and their relative affinity for the serotonin transporter on the risk of myocardial infarction. Circulation 108: 32-36.
44. Tousoulis D, Antoniades C, Drolias A, Stefanadi E, Marinou K, et al. (2008) Selective serotonin reuptake inhibitors modify the effect of β-blockers on long-term survival of patients with end-stage heart failure and major depression. J Card Fail 14: 456-464.
45. Glassman AH, O'Connor CM, Califf RM, Swedberg K, Schwartz P, et al. (2002) Sertraline treatment of major depression in patients with acute MI or unstable angina. JAMA 288: 701-709.
46. Serebruany VL, Glassman AH, Malinin AI, Nemeroff CB, Musselman DL, et al. (2003) Platelet/endothelial biomarkers in depressed patients treated with the selective serotonin reuptake inhibitor sertraline after acute coronary events: the Sertraline AntiDepressant Heart Attack Randomized Trial (SADHART) Platelet Substudy. Circulation 108: 939-944.
47. O'Connor CM, Jiang W, Kuchibhatla M, Silva SG, Cuffe MS, et al. (2010) Safety and efficacy of sertraline for depression in patients with heart failure: results of the SADHART-CHF (Sertraline Against Depression and Heart Disease in Chronic Heart Failure) Trial. J Am Coll Cardiol 56: 692-699.
48. Angermann CE, Gelbrich Gt, Stork S, Fallgatter A, Deckert J, et al. (2007) Rationale and design of a randomised, controlled, multicenter trial investigating the effects of selective serotonin re-uptake inhibition on morbidity, mortality and mood in depressed heart failure patients (MOOD-HF). Eur J Heart Fail 9: 1212-1222.
49. Liu L, Marcocci L, Wong CM, Park A-M, Suzuki YJ, (2008) Serotonin-mediated protein carbonylation in the right heart. Free Radic Biol Med 45: 847-854.
50. Hoeper MM, Welte T, Izbicki G, Rosengarten D, Picard E, et al. (2006) Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 354: 1091-1093.
51. Guilluy C, Eddahibi S, Agard C, Guignabert C, Izikki M, et al. (2009) RhoA and Rho Kinase activation in human pulmonary hypertension: role of 5-HT signaling. Am J Respir Crit Care Med 179: 1151-1158.
52. Zhai FG, Zhang XH, Wang HL, (2009) Fluoxetine protects against monocrotaline-induced pulmonary arterial hypertension: potential roles of induction of apoptosis and upregulation of Kv1.5 channels in rats. Clin Exp Pharmacol Physiol 36: 850-856.
53. Chambers CD, Hernandez-Diaz S, Van Marter LJ, Werler MM, Louik C, et al. (2006) Selective serotonin-reuptake inhibitors and risk of persistent pulmonary hypertension of the newborn. N Engl J Med 354: 579-587.
54. Chahal H, McClelland RL, Tandri H, Jain A, Turkbey EB, et al. (2011) Obesity and right ventricular structure and function: the MESA-Right Ventricle Study. Chest (in press).
55. Heckbert SR, Post W, Pearson GDN, Arnett DK, Gomes AS, et al. (2006) Traditional cardiovascular risk factors in relation to left ventricular mass, volume, and systolic function by cardiac magnetic resonance imaging: the Multi-Ethnic Study of Atherosclerosis. J Am Coll Cardiol 48: 2285-2292.
56. Aaron CP, Tandri H, Barr RG, Johnson WC, Bagiella E, et al. (2011) Physical Activity and right ventricular structure and function: the MESA-Right Ventricle Study. Am J Respir Crit Care Med 183: 396-404.
57. Wong CY, O'Moore-Sullivan T, Leano R, Hukins C, Jenkins C, et al. (2006) Association of subclinical right ventricular dysfunction with obesity. J Am Coll Cardiol 47: 611-616.
58. Henriksen E, Landelius J, Kangro T, Jonason T, Hedberg P, et al. (1999) An echocardiographic study of right and left ventricular adaptation to physical exercise in elite female orienteers. Eur Heart J 20: 309-316.
59. Willens HJ, Chakko SC, Lowery MH, Byers P, Labrador E, et al. (2004) Tissue Doppler imaging of the right and left ventricle in severe obesity (body mass index &35 kg/m2). Am J Cardiol 94: 1087-1090.